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Vascular Permeability Factor Expression 
Influences Tumor Angiogenesis in Human 
Melanoma Lines Xenografted to Nude Mice
Andy J.G. Pötgens,* Nicolette H. Lubsen,1- 
Margarethe C. van Altena,*
John G.G. Schoenmakers,t  Dirk J. Ruiter,* 
and Robert M.W. de Waal*
h'rom the Iustiliih vrsit)
'gen, a n d  the Department o f Molecular
University o f
♦
‘gen, ‘gen, Thi
We studied the expression o f the angiogenic fa c ­
tor vascular permeability factor) (VPF, also 
called vascular endothelial growth factor), in 
human melanoma cells in vitro and in viva Mela­
noma lines that develop tumors with a low meta­
static potential in nude mice were found to have 
low expression levels o f  VPF in vitro, and the 
VPF expression levels in melanoma lines that
metastatic xenografts ivere high. 
However, in vivo the correlation between VPF 
mRNA levels and the frequency o f  metastasis was 
lost; in all xenografts equally high levels o f  VPF 
mRNA were found, independent o f  the parental 
cell line. Hence, in vivo VPF gene expression was 
upregulated in the low expressing lines. The ex­
may
be hypoxia, given that we found that low oxygen 
tension caused a. ( reversible) increase in the VPF 
mRNA levels in otherwise low expressing mela­
noma lines in vltra A melanoma line with an in­
ducible VPF expression was engineered into a 
line with a constitutive VPF expression. In the 
xenografts from  this line a change in the vascu­
lar architecture was seen, indicating that the 
pattern or the level o f  VPF expression is impor­
tant fo r  tumor angiogenesis in melanoma xe-
nogt s. (Am f  Pathol 1995, 146:197-209)
ferent receptors for VPF have been characterized: 
fms-like tyrosine kinase (fit) and fetal liver kinase 1 
(flk-1/kinase insert domain-containing receptor). 
These appear to be expressed almost specifically by 
endothelial cells and hematopoietic cells.3 6 VPF is 
an important angiogenic factor, along with other fac­
tors such as acidic and basic fibroblast growth factor 
(aFGF, bFGF) and transforming growth factor-/3 (TGF- 
/3).7,8 Apart from its expression by some normal, well- 
vascularized tissues and embryonic tissues, and dur­
ing wound repair,9" 12 VPF has been found in many 
tumors and tumor cells.13 In glioblastoma VPF ex­
pression was found to be highest near necrotic areas, 
and clusters of newly formed capillaries were found 
around the sites of VPF production,14,15 suggesting 
that VPF can be recruited to augment angiogenesis 
if the tumor vasculature and therefore the oxygen sup­
ply is insufficient. The role of VPF in tumor angiogen­
esis was confirmed by blocking its activity in tumors 
by a monoclonal antibody, and by application of a 
dominant-negative VPF receptor mutant.m ,/  These 
treatments led to a decrease in angiogenesis and to 
slower tumor growth.
Several protein variants of VPF exist because of 
alternative splicing of the VPF mRNA. The molecular 
variants differ in their efficiency of secretion. The 
smaller forms ( V P F , and VPF„i;,) are efficiently se­
creted by the producing cells, and can easily reach 
their target cells. The larger forms (VPF fM<t and 
VPF™,;) are retained at the extracellular matrix, but 
biologically active parts of these proteins can be re-
leased by plasmin. in ;'ii Theoretically, different cell
types may benefit from particular VPF variants. 
Tissue-specific expression of certain VPF messenger 
variants has indeed been demonstrated.19,21
As a consequence of its proposed role in tumor 
angiogenesis, VPF may also facilitate metastasis, as
Vascular permeability factor (VPF), also known as 
vascular endothelial growth factor, is a glycosylated, 
secreted protein factor that increases blood vessel 
permeability, stimulates endothelial cell division in 
vitro, and induces angiogenesis in wVo.1,s Two dif-
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this process is dependent on the vascular bed.22 To 
study the relation between VPF expression and me­
tastasis, a panel of human melanoma cell lines was 
used. Xenografts of these melanoma lines in nude 
mice give rise to tumors with distinctly different bio­
logical behavior. Some of these lines develop into t 
rapidly metastasizing tumors, whereas other lines 
metastasize at a low frequency or very slowly (see 
ref. 23; J.R. Westphal, J.A.W.M. van der Laak, C.J.M. 
Schalkwijk, D.J. Ruiter, R.M.W. de Waal, manuscript 
in preparation). The metastatic phenotype of these 
lines was found to correlate with the expression of a 
series of genes or antigens, such as urokinase-plas- 
minogen activator and its type 1 inhibitor, various 
integrins, the epidermal growth factor receptor, thy­
mosin j810, and calcyclin.24-28 We report here that 
low and highly metastatic melanoma lines have dis­
tinctly different expression patterns of VPF. Highly 
metastatic melanoma lines have constitutively high 
levels of VPF expression, whereas the less meta­
static lines have a low level of VPF expression in 
culture, which is elevated in mouse xenografts. In 
vitro data suggest that hypoxia may be an important 
trigger in this upregulation of VPF gene expression. 
Transfection experiments show that an alteration of 
VPF expression in melanoma xenografts profoundly 
affects vascular architecture. Hence, at least in this 
melanoma model, the VPF expression pattern is an 
important determinant of angiogenesis, and possibly 
of angiogenesis-dependent biological behavior.
Materials and Methods
Cell Culture
Human melanoma cell lines were cultured as previ­
ously described.23 Transfected melanoma lines were 
cultured in medium supplemented with 200 pg/ml 
hygromycin B (Boehringer Mannheim, Germany). 
Human brain capillary pericytes were isolated and 
cultured as described elsewhere.20 U937 cells and 
Balb-3T3 cells were from American Type Culture Col­
lection (Rockville, MD) and cultured In Dulbecco’s 
Modified Eagle’s Medium (DMEM, Flow Laborato­
ries, Irvine, UK) with 10% fetal calf serum (FCS, 
Gibco BRL, Paisley, UK), 2 mmol/L L-glutamine and 
40 jjg/ml gentamycin (Schering Corporation, Am- 
stelveen, The Netherlands).
Melanoma Xenografts
Human melanoma cells were trypsinized and 2 x  106 
cells were injected s.c. into BALB/c nu/nu mice as 
previously described.23 Xenografts were dissected at
different time points after inoculation, measured, rap­
idly frozen in liquid nitrogen, and stored at -70 C.
Isolation of RNA
RNA was isolated from cultured cells either using LiCI/ 
urea,30 or using guanidinium chloride.31 RNA from 
tumors and normal murine tissues was isolated after 
disruption in guanidinium isothiocyanate by CsCI 
centrifugation.32 RNA concentration was determined 
spectrophotometrically at 260 nm.32
Northern Blotting and Probes Used
Samples of total RNA were denatured in 50% form- 
amide in formaldehyde/phosphate buffer (65 mg/ml 
formaldehyde, 25 mmol/L NaH2P04/Na2HP04, pH 
7.0) for 15 minutes at 55 C, run on a 1% agarose gel 
in formaldehyde/phosphate buffer, and blotted to ni­
trocellulose membranes.32 As a probe for VPF mRNA, 
a fragment was used which comprised the protein 
coding region of VPF165. To isolate this fragment, a 
reverse transcriptase (RT) polymerase chain reaction 
(PCR) was performed on RNA from phorbol 12- 
myristate 13-acetate-treated U937 cells,1 using re­
verse primer (5'-TTCCTCCTGCCCGGCTCACCG-3') 
and forward primer (5'-CCCGGTCGGGCCTC- 
CGAAACCA-3'). Blunt-ended PCR products were 
cloned into Smal-digested pUC19 vector DNA and 
characterized by sequencing. PCR products from the 
alternatively spliced messengers for VPF121, VPF165, 
and VPF189 were identified. A 0.6-kb VPF165 insert 
was isolated as an Xjbal/Kpnl-fragment and labeled. 
Control hybridizations were performed with a human 
ubiquitin probe,33 a human 0-actin probe,34 or with a 
Drosophila ribosomal RNA probe. Fragments were la­
beled with [cv-32P]dATP after random hexamer prim­
ing.35 Northern hybridizations were performed in 50% 
formamide, 6 x  SSC, 0.1 % SDS, 0.1 mg/ml denatured 
herring sperm DNA and 5 x  Denhardt's32 at 45 C, 
followed by washing in 0.2 x  SSC, 0.1% SDS at 65 C. 
Intensities of hybridization bands were scanned with 
an Ultroscan XL Enhanced Laser Densitometer from 
LKB (Bromma, Sweden).
Analysis of Alternatively Spliced 
VPF mRNA
2 to 8 pg of total RNA isolated from cell lines or mela­
noma xenografts was reverse transcribed using 0.5 
jjg reverse primer (5'-TTCCTCCTGCCCGGCTCA- 
CCG-3'), 0.4 mmol/L deoxyribonucleotides (dNTPs; 
Pharmacia LKB, Woerden, The Netherlands), five
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units avian myeloblastosis virus (AMV)-RT (Strat- sity, cells were scraped and lysed, and the cellular
agene, San Diego, CA), five units RNasin (Boehringer protein content was determined by a standard protein
Mannheim), and reaction buffer provided by Strat- assay (Bio-rad, Veenendaal, The Netherlands).
agene, in final volumes of 10 ¡jI, for 1 hour at 42 C. Based on this protein determination, samples of con-
After ethanol precipitation and redissolving in 10 pi ditioned media derived from equal amounts of cell
distilled water, half of the cDNA was used in PCRs material were taken, and proteins were acetone pre-
containing 0.3 pg reverse primer (see above), 0.3 pg cipitated, electrophoresed on 17.5% polyacrylamide
forward primer (5'-GCACCCATGGCAGAAGGA- 
GGA-3'), 0.2 mmol/L dNTPs, and 0.25 units Supertaq
gels under reducing conditions, and electroblotted to 
nitrocellulose membranes. Antisera against VPF wore
polymerase and reaction buffer provided by HT Bio- raised in rabbits using purified VPF produced in a
technology (Cambridge, UK) in final volumes of 25 pi. bacterial expression system. Antiserum was diluted
20 cycles of 1 minute at 96 C, 1.5 minutes at 52 C, and 1:100 or 1:250 for detection of VPF on Western blots,
4 minutes at 72 C were performed. 5 pi of every re- and the immune reactions were visualized using the
action mix was transferred to a new tube containing chemiluminescent substrate AMPPD (Tropix, West-
the same reagents, for one more cycle (6 minutes at burg, Leusden, The Netherlands) following the manu-
72 C). 10-pl samples of the products were separated facturer’s protocol. The crude antisera had some non-
on a 1.5% agarose gel, Southern blotted to nitrocel specific reactivity toward some bands of higher
lulose and probed with the VPF165 fragment in form- molecular weight than VPF on Western blots. Where
amide hybridization mix at 42 C. indicated this was diminished by affinity purification of
anti-VPF antibodies using purified Escherichia coli-
Determination of the Species Origin of
produced VPF absorbed by nitrocellulose mem-
I 0 7branes.
VPF mRNA
1 to 12 pg total RNA isolated from human cell lines, VPF Induction Experiments
murine tissues, or melanoma xenografts was reverse 
transcribed using 0.5 pg reverse primer (5'-TTGGT- 
GAGGTTTGATCCGCAT-3'), 0.4 mmol/L dNTPs, 5 
units AMV-RT, 10 units RNasin, and reaction buffer 
provided by the supplier of AMV-RT (Stratagene) in 
final volumes of 10 pi for 1 hour at 37 C. After ethanol 
precipitation and redissolving in 10 pi distilled water, 
half of the cDNA was used in PCRs containing 0.3 pg 
reverse primer (see above), 0.3 pg forward primer 
(5'-CGAAACCATGAACTTTCTGCT-3'), 0.2 mmol/L 
dNTPs, 0,25 units Supertaq polymerase, and reaction 
buffer provided by FIT Biotechnology, in final volumes 
of 25 pi. 20 cycles of 1 minute at 96 C, 1.5 minutes at 
48 C, and 2.5 minutes at 72 C were performed. 1-pl 
samples of the products were transferred to new 
tubes with all the PCR reagents, and subjected to one 
more cycle (10 minutes at 72 C). PCR products were 
then precipitated and redissolved. One-third was di­
gested with five units Sty\, which only cleaves the hu-
man product, separated on a 1.5% agarose gel,
Southern blotted, and hybridized with the VPFU;; 
probe.
The response to serum, fibroblast-conditioned me­
dium, or growth factors/cytokines was tested after 
preculturing subconfluent melanoma cell cultures in 
DMEM without serum for 24 hours. Medium was then 
replaced for 4 or 24 hours by DMEM with 10% FCS, 
or by DMEM (with and without FCS) conditioned by 
Balb-3T3 cells for 24 hours. Alternatively, serum-free 
medium was replaced for 4 hours by DMEM contain­
ing 0.1% bovine serum albumin and one of the fol­
lowing growth factors or cytokines: 5 ng/ml EGF (Col­
laborative Research, Bedford, MA); 5 ng/ml TGF-<* 
(Bachem, Bubendorf, Switzerland): 2 ng/ml TGF-01 
(R & D Systems, Minneapolis, MN); 10 ng/ml platelet- 
derived growth factor AA (PDGF-AA, a gift from Dr. 
C.H. Heldin, Uppsala, Sweden); 100 ng/ml bFGF (a
gift from Scios Inc., Mountain View, C A );..100 ng/ml
VPFio;, (in culture supernatant of COS cells trans­
fected with plasmid containing VPF1(iil cDNA under 
control of an SV40 early promoter); 50 ng/ml INF-«; 
100 units/ml interleukin-4 (IL-4); 400 units/ml inter­
feron gamma (IFN-y) (TNF-«, IL-4, and IFN-y were 
from Boehringer Ingelheim, Germany) 100 units/ml IL-
1ß; 50 units/ml IL-2 (IL-1 ß and IL-2 were from Gen »
Analysis of Secreted VPF Protein zyme, Sanbio, Uden, The Netherlands). Hypoxia ex­
periments were performed using subconfluent
Melanoma cells were cultured for 24 hours in serum- 
free medium when indicated with 100 ug/ml heparin.
melanoma cell cultures in 10 mmol/L Hepes-buffered 
DMEM with 10% FCS. Rubber-capped flasks were
Conditioned media were centrifuged and used for flushed for 1 hour at room temperature with 30 vol-
VPF analysis. To correct for differences in cellular den- umes of nitrogen made oxygen-free using a BASF R
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3-11 catalyst (BASF, Ludwigshafen, Germany). 
Oxygen-free C 02 was added up to 5%, and the flasks 
were then placed back at 37 C for the indicated times. 
At the end of each Incubation, gas samples were 
tested for 0 2 content by gas chromatography, and the 
pH of the media were determined. In some cases, the 
P0n of the media were also determined (CIBA-Corning
C.J.M. Schalkwijk, D J. Ruiter, R.M.W. de Waal, manu­
script in preparation), and which is suitable for the 
examination of tumor vasculature. Also, tumor sec­
tions were stained with a polyclonal rabbit anti-mouse 
lamlnin antiserum (provided by Dr. J. van den Born, 
Department of Nephrology, Nijmegen, The Nether­
lands).
288 Blood Gas System, Houten, The Netherlands). 
Control experiments were performed (in air/5% C 02) 
to investigate the influence of the pH of the medium. 
To achieve a low final pH, cells were grown In Hepes- 
buffered medium for several days, and to achieve a 
high pH medium was replaced for 6 hours by Hepes- 
buffered fresh medium preincubated In air for 1 hour.
Production of Stably Transfected 
Melanoma Lines
The protein coding region of VPFi2i was cloned di- 
rectionally as a Xba\/Kpn\ fragment into the expres­
sion vector EBOpLPP,38 by which the sequence was 
brought under control of SV40 transcriptional ele­
ments. This plasmid also codes for the hygromycin 
phosphotransferase (HPH) gene. The recombinant 
plasmid and the empty vector were digested with 
Apa\, thus eliminating some nonessential sequences. 
The residual 8-kb fragment was transfected into 
Mel57 cells by calcium phosphate precipitation fol­
lowed by a 3-minute shock with 25% DMS0.31 After 
48 hours the cells were trypsinized, seeded sparsely 
in culture flasks, and selected in medium with 200 
pg/ml hygromycin B (Boehringer Mannheim). Single 
resistant colonies were removed by scraping and 
grown until analysis of VPF expression, and storage 
of stocks in liquid nitrogen was possible.
Histological Analysis of Tumors from 
Transfected Melanoma Lines
Transfected melanoma lines were inoculated in nude 
mice as described above. Every line was injected in 
at least two mice on both flanks. Tumor volumes were 
measured weekly, and growth curves were prepared. 
Tumors of sizes between 150 and 800 mm3 were ex­
cised 30 to 60 days after inoculation, and cut Into 
three fragments. One part was formalin-fixed and 
used to study overall tumor morphology. The other 
parts were snap frozen in liquid nitrogen; one was 
used for RNA isolations, the other to study the vas­
cular patterns and the organization of stroma and ex­
tracellular matrix. Cryosections were stained with 
monoclonal 9F1, which reacts specifically with mouse 
endothelium (J.R. Westphal, J.A.W.M. van der Laak,
Results
Analysis of VPF mRNA in Cultured 
Melanoma Cells
The four melanoma cell lines IF6, Mel57, BLM, and 
MV3 differ in metastatic potential upon s.c. Injection 
in nude mice.23 To determine whether this behavior 
correlates with VPF expression, RNA was Isolated 
from these cell lines and examined by Northern analy­
sis. VPF mRNA was readily detectable In RNA from 
the cell lines BLM and MV3 (Figure 1) as a major band 
of 3.7 kb. RNA from the cell lines IF6 and Mel57 
showed only very weak hybridization signals with the 
VPF probe. The highest VPF mRNA levels were thus 
found in the cell lines BLM and MV3, which were
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Figure 1. Northern blot analysis of VPF mRNA in melanoma cell 
lines. / sampl es o f  i.iCl/urea isolated RNA were loaded in each 
lane. (A) VPF hybridization . (B) Ubitjuiiin hybridization, Only rel­
evant f)arts of the ciutoradiograins are shown. Positions o f  RNA size 
markers are shown on the left.
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shown in earlier studies to give rise to highly meta­
static tumors in nude mice. The other lines, which had 
a low level of VPF mRNA expression, produced tu­
mors with a much lower metastatic frequency.23
The observed difference in expression of VPF 
mRNA is not likely to be caused by a genomic rear­
rangement or an amplification of the VPF gene. South­
ern analysis of the genomic DNA isolated from these 
melanoma lines and from normal human buffy coat 
showed no obvious differences in intensities of the 
bands hybridizing with a VPF probe, nor were shifts 
of bands or extra bands observed in any of the mela­
noma lines (data not shown).
Alternatively spliced messengers of VPF cannot be 
distinguished by Northern blotting. To determine 
whether the melanoma lines differ in the ratio of these 
mRNA variants, an RT-PCR was performed, which 
amplified the alternatively spliced region of the mes­
senger. RNA from all the melanoma cell lines yielded 
the same pattern in that the product from the RNA 
coding for VPF121 was the most prominent (52 to 
70%), followed by the VPF165 product (26 to 42%). 
The VPF-,89 mRNA was in all cases found to be a minor 
species (4 to 8%), whereas no VPF206 mRNA was 
found in any of the melanoma cell lines (Figure 2, 
lanes 2 to 5). No correlation between the biological 
behavior of the melanoma lines and the predomi­
nance of the VPF variants produced could therefore 
be demonstrated. The observed ratio of splice vari­
ants does not seem to be specific for melanoma cells 
or even for tumor cells, as the same ratio of splice 
variants was found in RNA from the human lymphoma 
cell line U937 and in RNA from normal human peri­
cytes (Figure 2, lanes 6 and 7).
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are expected from mouse VPF mRNA. as the primer's do not match the 
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Levels of Secreted VPF Protein Correlate 
with the VPF mRNA Levels
The amount of VPF protein secreted from the mela­
noma cell lines was determined by culturing the cells 
In serum-free medium containing heparin, to release 
also the longer VPF variants from the extracellular ma­
trix.20 The proteins in the conditioned medium were 
Western blotted and stained with a polyclonal anti­
body against VPF. In the conditioned media from cell 
lines BLM and MV3 detectable amounts of VPF were 
present. Several bands with apparent molecular 
weights between 17 and 25 kd were identified (Figure 
3), which agree with the expected sizes of non­
glycosylated and glycosylated V P F i 21 and
VPF165.19'20 VPF189 and VPF206 (expected around 30
kd) could not be found, supporting the finding that 
their mRNAs are poorly expressed In melanoma cells 
(Figure 2; the band In the MV3 lane at 38 kd Is prob­
ably caused by a dimer of VPF12i or by a nonspecific 
reaction rather than by a monomeric form of one of the 
larger VPF variants). In conditioned media from cell 
lines IF6 and Mel57 no VPF could be detected, which 
agrees with the fact that these cells contain low 
amounts of VPF mRNA (Figure 1). These results in-
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Figure 3, Western blot analysis of VPF in conditioned media from  
melanoma cells. Gmjluent atllures of melanoma cells were grown in 
serum free medium with 100 ng/ml heparin for 24 hours, Precipi­
tated proteins from 0.225 to 0,7 ml conditioned media { but derived 
from the same amount of cellular mass) were subjected to SDS-PAGE 
taider reducing conditions, Western blotted, and stained with 
affhiityintrified antiserum against VPF Molecular weight markers 
are shown on the right.
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dicate that the levels of VPF mRNA In melanoma cells 
are reflected in the levels of VPF protein expression.
Analysis o f Melanoma Xenograft RNA
To determine whether VPF mRNA levels change when 
melanoma cell lines form tumors in nude mice, RNA 
isolated from melanoma xenografts was examined. 
The four melanoma lines that were also used in the 
above experiments (IF6, Mel57, BLM, and MV3) were 
injected in mice, and the resulting tumors were col­
lected at different time points after injection. All xe­
nografts contained comparable levels of VPF mRNA 
(Figure 4), including those derived from the lines IF6 
and Mel57, which had hardly detectable levels of VPF 
mRNA in culture. Scanning of autoradiograms from 
blots containing both cell line RNAs and xenograft 
RNAs (not shown) revealed that the average VPF 
mRNA level in xenografts was 75% of the average 
level in the cultured cell lines BLM and MV3 (range 30 
to 170%). The small differences between the VPF 
mRNA levels in xenografts were independent of the 
parental cell line. The levels of VPF mRNA did tend to 
decrease with increasing tumor size for those tumors 
that were derived from the IF6, Mel57, and MV3 lines, 
but in tumors derived from cell line BLM the opposite 
effect was seen, namely an increase in the VPF mRNA 
level with increasing tumor size (Figure 4). No change
in the splicing pattern was found in xenografts: the 
ratios of alternative splicing products were equal to 
those in the cultured cell lines (Figure 2, lanes 8 to 11).
The VPF messengers found in melanoma xe­
nografts could derive from melanoma cells, but also 
from host cells within the tumor (stromal cells) or from 
small amounts of surrounding tissue (eg, skin). VPF 
mRNA was indeed found in some murine tissues such 
as skeletal muscle and heart, but was not detected in 
normal mouse skin (Figure 5). These normal mouse 
tissues are not readily comparable, however, with 
host tissue within melanoma xenografts. To confirm 
the melanoma origin of the xenograft VPF mRNA un­
equivocally, an RT-PCR assay was carried out which 
discriminates between human and murine VPF se­
quences. RNA was reverse transcribed and amplified 
using a set of primers based on sequences common 
to both the human and murine VPF messenger. PCR 
products were then digested with Sty\, which cleaves 
the human, but not the murine sequence. As pre­
dicted, a 0.35-kb band was found when RNA from 
murine tissues was used, whereas two products of 
—0.25 and 0.1 kb (the latter only slightly visible) arose 
from human RNA (Figure 6). Although xenograft
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Figure 4. Northern blot MuiJysis o f  VPF mRNA in melanoma xe~ 
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HO m m 1; Met57~X2: 31 days, 1200 m m 1; Mel57~X3: 45 days, 1340 
mm {; MV3-XI; 31 days. 490 m m \  MV3-X2: 31 days, 3400  m m 1: 
A11 ; i' 4 5 cla) iv, / <S\ 750 m m 1; BLM~X 1: 24 cUi) '.s'. 6000 m m l; HIJ1 
X2: 2* i da\ % J ()()()() mm*, (A) VI *F b ) i> / id  izatU m, (B ) If hi (¡nit in h\ 
bridizatiou, Only relevant parts o f  the autoradiograms are shoivu 
i'ositions o f  RNA size markers are indicated on the left.
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Figure 5. Pn>saice o f  mRNA fo r  VPF in motisi* organs, 10 to I(>■7ig 
samples o f  total RNA were loaded in each lane, S, skin; M, skeletal 
miisck>; I f  hea 1 */; .A, lit er, (A ) VPF by*h/idizalion. ( B ) the 2HS siguat 
upon hybridization with a nhosomal probe, Positions o f RNA size 
markets aresbotvn on the left.
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Figure 6. Determination of tin* species origin o f  VI *P in RNA, R’FPCR 
followed by I-digest nyti was performed t>n RNA from nations 
sources to determine the origin o f  the VPF messengers, as explained 
in Materials an d  Methods, Lanes 1 to , i  hitman veil line RNAs; lanes 
4 to mouse RNAs (skeletal muscle a n d  heart); lane 6, no RNA; 
lanes 7 to 15 melanoma xenograft RNAs (see also legend to Figure 
4). A Southern hlot urn hybridized with a VPF probe and washed in 
2  X SSC at 50 C. Subset¡uent trashing in 0.2  X SSC at W  C d id  not 
change the pattern. Positions o f  DNA size markers are indicated on 
the left. Iixpevted fragments Jhtm hitman VPF mRNA. 25(> a n d  90 bp; 
from murine VPF mRNA, 34J bp.
RNAs were amplified to different extents, leading to 
varying amounts of total PCR product, a consistent 
pattern was seen. In all cases, the human-specific 
band of 0.25 kb was the most prominent product. The 
mouse-derived 0.35-kb band was also present in all 
xenograft RNAs, but its intensity was only 14 to 25% 
of that of the human-derived band. The majority of the 
xenograft VPF mRNA is thus synthesized by the hu­
man melanoma cells. For IF6 and Mel57 cells this im­
plies that the expression of VPF is distinctly higher in 
wVothan in vitro, and that in vivo their VPF expression 
Is no longer different from that in the cell lines BLM and 
MV3.
Influencing VPF Gene Expression
Apparently, VPF mRNA levels are induced in IF6 and 
Mel57 cells during tumorigenesls in nude mice. To 
investigate possible mechanisms that could contrib­
ute to this induction, Mel57 cells were exposed in vitro 
to factors that may also have been present in vivo. 
After serum deprivation, the cells were incubated for 
4 or 24 hours in serum-containing medium, in medium 
conditioned by mouse fibroblasts (Balb-3T3 cells) 
with or without serum, or in serum-free media to which 
a growth factor or cytokine (listed in the Materials and 
Methods section) was added. No increase in the VPF 
mRNA levels was found (not shown). IF6 cells also did 
not respond to addition of serum or Balb-3T3- 
conditioned medium. Hence, growth factors or cyto­
kines present in serum or fibroblast-conditioned me­
dium, or added separately, apparently do not 
augment VPF messenger levels under these condi­
tions. When Mel57 cells were cultured in low oxygen 
tension for 6 or 24 hours, however, a dramatic In­
crease in the VPF messenger content was found (Fig-
ure 7). After reoxygenation of the flasks these levels 
started to decrease; within 3 hours a reduction of 50% 
was observed (Figure 7, lanes 5 and 6). No effect on 
the VPF mRNA levels was seen when the pH of the 
medium was varied between 7.2 and 8.1 (Figure 7, 
lanes 1 and 2), which excludes the possibility that pH 
differences due to the hypoxic treatment caused the 
observed induction. In IF6 cells cultured under low 
oxygen tension for 24 hours, a dramatic induction of 
the VPF mRNA level was found as well (not shown). 
The absolute induction of VPF messenger levels 
reached in Mel57 and IF6 cells after 24 hours of hy­
poxia cannot be measured, as hybridizing bands are 
hardly visible in the uninduced state. The maximally 
induced VPF mRNA levels in Mel57 and IF6 cells were 
1.3- and twofold the already high basal level in MV3 
cells, respectively. The high level of VPF mRNA in MV3 
cells could further be increased by a factor of three 
when cultured in low oxygen levels (not shown). 
These results show that hypoxia increases VPF mRNA 
levels in melanoma cells such that cell lines with dis­
tinctly different levels under normal conditions reach 
comparable levels under conditions of low oxygen 
tension. Relative levels of VPF splice variants were 
analyzed and found unaltered upon hypoxic shock in 
Mel57, IF6, and MV3 cells (not shown).
A (kb)
4 . 4
mrq
' ' ' • '
2 .4
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1 . 4 filili.
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Figuro 7. Induction of  17 *F m RNA in Mel 5? a  'Ils by hypoxia. (, \ ‘Its 
were cultured under nitrogen, as described in Materials an d  Meth 
(nls. At the end o f  the incubations, oxygen lei vis in the gas phase were 
OS to 1.0% and  Pn< raines in the media tecrc J.ti to J ,0  kPa . Control 
cells were incubated in a ir/5% C tu  in media o f  different fd I, Final 
p i i  values o f  the media are indicated . H to 22 pg samples o) guani 
din turn chloride isolated RNA teere loaded in each lane. Lane L tar 
C<>,\ pU  S\ I; lane 2: air ' C O p H  7.2; lane .1 A,. /lushed an d  5 hoars 
in a i r / C O p H  ?S; lane 4: U hours in Nj <,‘f k, pH  7 <v, lane ^  24 
bout's iti N,> ( '( >,\ fill 7.5 lane (>; 20 Inacrs in /Y - r ( and  J  bouts iti 
air ('(I*. pH  "V/. (A) VPF hybridization. <B) ft actin byhridtzuiiun 
Flrùjuitiu u'as not used as a control, bectttise the cxfnvssioti o f  this 
getw may be altered in stress situations. Positions oj RNA size m ark­
et's are shotvn on the left,
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Production of a VPF-Overproducing 
Transfectant Melanoma Line
To determine whether the pattern of VPF expression, 
constitutive versus inducible, actually makes a dif­
ference in the process of angiogenesis and perhaps 
metastasis during the development of the melanoma 
xenografts, we transformed a VPF inducible line into 
a VPF constitutive line by stably transfecting a con­
struct containing the protein coding region of VPF1g1, 
the VPF variant most abundantly expressed in mela­
noma cells (Figure 2), into cell line Mel57. The result­
ing transfectants should have a constitutive VPF ex­
pression (as in lines MV3 or BLM) instead of an 
inducible VPF expression, As a control, Mel57 cells 
were also transfected with vector DNA without a VPF 
sequence. A number of stable transfectant lines were 
examined for expression of recombinant VPF RNA, 
which Is easily recognizable as It is much shorterthan 
endogenous VPF mRNA (see Figure 8). The trans­
fectant line I-3 had the highest level of recombinant 
VPF RNA and was used for further study. Medium 
conditioned by these cells contained clearly detect­
able levels of nonglycosylated and glycosylated 
VPF-,21 visible as bands of 17 and 20 kd on a Western 
blot stained with polyclonal anti-VPF. The vector- 
transfected line E2, which did not show any signs of 
(recombinant) VPF RNA or protein expression (Figure 
8), was used as control in further experiments.
VPF-transfected line I-3, control transfected line 
E2, and the parental cell line Mel57 were injected into
Cell lines Xenografts
E2 1-3
I A
kb
4.4
» #
2.4
1.4
E2 1-3 E2 1-3 kD_I . 1
II
#
2.4
B
■W0/ 
■fit?
66
i
45
31
21.5
14.4
FI g u re 8. lixpress ion of recoin hi i ¡cm I VPF RNA a t i d prott >i 11 by ini us- 
fected melanoma lines. (I) RNA isolated from control- (F2) and  VPF 
( l\i)-transfected cell lines i left, 10 to 15 pg RNA loaded in each lane) 
an d  from their resjK’ctiee xenografts in nude mice ( center, 22  to 30 
! °J * RNA la tided i t / ea cb lane). ( IA ) VPF hybridization (with endo­
genous VPF messenger bands at j . 7  kbt and  recombinant VPF RNA 
ha ì t ds at 1 kb). (IB) Uh iq u iti n h j *h t iti izat io n. Only retei •ant pa rts < >f 
the Northern blots are shown. (II) Proteins from 0,2 ml scrum free  
co nd it io ned medi a < \f tra n sfeci ed lui os F2 and  / .  j were act •tot i « » p n  
cip ita ted, elect ropho resod on SDS-PAGlu electro! dotted, and  stained 
with crude antiserum against VPF Specific staining fo r  VPl'/jj  is ob< 
sen v d  at 17 to 20  kd. A /so so me not ispecific sta in it tg o f  h igf.u v  mo 
lea  da r u vigb t ha nds Is t isi Me in In )th Ian os. 1 *t >s it U > i is o f  mt >h >ci t It t r 
weight markers are indicated on the right,
nude mice. The tumors that developed after inocu­
lation of line 1-3 still expressed the 1-kb recombinant 
VPF RNA, but the endogenous 3.7-kb VPF messenger 
was detectable In these tumors as well (Figure 8). The 
upregulatlon of VPF mRNA was only a minor contri­
bution to the total amount of VPF RNA produced in 
these tumors; the band intensities of VPF mRNA were 
only about 50% of the intensities of the recombinant 
VPF RNA bands. Tumors from control transfected line 
E2, as expected, had elevated levels of VPF mRNA 
but did not show recombinant VPF RNA. Tumors from 
line E2 did express the vector-encoded hygromycin 
phosphotransferase RNA (not shown).
Vascular Architecture In Transfectant 
Xenografts
Tumors from the parental and the transfected cell 
lines did not differ significantly in growth rate, nor did 
they differ in their extent of necrosis (as judged from 
HE-stained cross sections). Staining of cross sections 
with the monoclonal antibody 9F1, which reacts spe­
cifically with mouse endothelium, showed that the 
vascular pattern in tumors from VPF-transfected line 
-3 was clearly different from the pattern in tumors 
from the control lines. Tumors from control lines Mel57 
and E2 had similar vascular patterns. Typically, in tu­
mors from control lines blood vessels always ap­
peared separately. Large vessels with iumina were 
visible as well as smaller microvessels and capillary 
sprouts in which no lumen could be observed upon 
light microscopy. Between different regions within 
one tumor, differences in vessel density did occur: 
some tumor parts were well vascularized and viable, 
whereas other parts were poorly vascularized and 
highly necrotic. In regions with a low density of ves­
sels, as in the section shown in Figure 9A, vessels 
were surrounded by a layer of viable tumor cells, while 
at a greater distance tumor tissue was necrotic. Tu­
mors from VPF-transfected line i-3 had quite a differ­
ent arrangement of blood vessels (Figure 9B). Ves­
sels formed a dense network around nodules of tumor 
cells. The endothelial staining in cross sections ap­
peared to be largely continuous, suggesting that 
there is a three-dimensional plexus of blood vessels 
surrounding the tumor nodules, Within the tumor nod­
ules very few or no blood vessels were present, often 
leading to viable layers of tumor cells surrounding 
necrotic centers.
Staining for the extracellular matrix component 
laminin showed that in tumors from both the control
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Figure 9. Wsuttliuuioii o f  tumor ivsscls urn! kiminin in tump's fm m  transfected melanoma linos, Cross sections t ivn * shtiucd with monockmal 
1>I’I /hr entlotheliumhlood vessels i A, B l  magnification ttfix, or with rahhit am im ouse  laminiu (C, D), magnificat km j o o x  , (A, C.) r> tw  sections 
of line l\2 tlent'cd Minot's (B. D) <>oss s a t  ions of tumtus from \'l'I‘ transfected line /  .!, Arrowheads ¡mint to areas o f  necrosis.
lines and the VPF-overproducing line tumor nodules 
were surrounded and separated from each other by 
stromal septa (Figure 9, C and D). However, on the
larger than those in control tumors, and the stromal
component consisted for a large part of endothelial
cells (Figure 9B), unlike the situation in control tumors, 
in
9A), The change in the
m
cular architecture in t 
melanoma line.
Discussion
whether the level of VPF expression in several human 
melanoma lines correlated with the metastatic poten­
tial of these lines in nude mice. We did observe this 
correlation in cultured melanoma cells: lines IF6 and 
Mel57, which produce rarely or slowly metastasizing 
tumors, had much lower levels of VPF mRNA and se­
creted less VPF protein than lines BLM and MV3, 
which develop into highly metastatic tumors in mice 
(see ref. 23; J.R. Westphal, J.A.W.M. van der Laak,
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C.J.M. Schalkwijk, D.J. Ruiter, R.M.W. de Waal, manu­
script in preparation). However, these differences in 
VPF expression were no longer observed in vivo; tu­
mors from all four melanoma lines had high levels of 
VPF mRNA, produced mainly by the melanoma cells. 
Therefore the highly metastatic melanoma lines have 
a constitutive VPF expression, which apparently is not 
dependent on the extracellular environment, while the 
less metastatic lines can have the same level of VPF
melanoma lines, one in which VPF mRNA levels were 
upregulated by hypoxia, and a second in which VPF 
mRNA levels were only slightly affected by oxygen 
tension. Further evidence for the assumption that hy­
poxia is the major trigger for the VPF mRNA upregu- 
lation observed by us in vivo can only be provided by 
in situ hybridization or by immunohistochemistry. 
These experiments are in progress in our laboratory.
A relation between tumor angiogenesis and me-
expression, but only if it is induced by external factors.
The upregulation of VPF expression in iF6 and 
Mel57 cells in vivo might have been caused by protein 
factors released by, eg, stromal cells. In several cell 
lines, induction of VPF expression by TGF-jS and
tastasis has been postulated on theoretical grounds 
and has also been demonstrated in practice in sev­
eral tumor types including melanoma.8,46“49 Given 
that VPF is a potent angiogenic factor, it might also 
play an important role in the development of the meta-
PDGF-BB has been demonstrated.39-41 We did not static phenotype of melanoma xenografts. Although
find any induction of VPF mRNA by various growth the xenografts of all melanoma lines examined
factors or cytokines, serum, or conditioned media of showed comparable VPF expression, this expression
fibroblasts in the melanoma cells IF6 and Mel57. We in the less metastatic lines IF6 and Mel57 has to be
cannot, however, exclude the possibility that other upregulated first in vivo. A lower expression level of
growth factors or combinations of such factors can VPF In early IF6 and Mel57 xenografts might result in
cause an increased VPF expression in these cells. a delayed development of the vascular bed com-
One of the mechanisms that may lead to enhanced pared with BLM and MV3 xenografts, which might
VPF expression in vivo is hypoxia, given that a dra- eventually hamper the opportunities for dissemina-
matic upregulation of VPF messenger levels was evl- tion. To separate the effect of VPF expression on the
dent after incubation of Mel57 and IF6 cells under low vasculature from the effects of other factors (differ-
oxygen pressure. VPF expression was already known entially) produced by the various melanoma lines, it
to be induced by hypoxia in glioma and hepatoma is necessary to manipulate VPF expression in one of
cells14'42; also, the expression of a number of other 
genes is induced by hypoxia. The intracellular
the melanoma lines.
By transfection into cell line Mel57 of a VPF121 se-
mechanlsms responsible for this kind of induction are quence, we were able to produce an Mel57-derived
only beginning to be understood.43,44 There is evi- cell line that had a constitutively high expression of
dence that an intracellular heme protein is involved in VPF. In this way it was possible to study the biological
hypoxia-induced expression of both VPF and eryth- behavior of tumors from melanoma lines with an in-
ropoietin, and this effect of hypoxia on glioma and ducible or a constitutive VPF expression in an other
hepatoma cells is mimicked by cobalt chloride.42 VPF wise unchanged genetic background. The arrange
mRNA levels In Mel57 cells were also upregulated by 
cobalt chloride (not shown), suggesting a regulatory
ment of the tumor vasculature Indeed turned out to be 
quite different in tumors resulting from the constitutive
mechanism that is common to many cell types. In MV3 VPF-expressing transfectant line. In another study,-’0
cells, which have a higher expression of VPF mRNA two types of vascular branching in tumors were dis-
than Mel57 and IF6 cells when cultured under nor- 
moxic conditions, VPF mRNA induction by hypoxia
tinguished. "Tumor-penetrating branches of variable 
diameter" were found in some tumors, and "lateral
was relatively small. These cells may have undergone surface branches that formed an arborizing and
an irreversible switch to a high VPF producing phe- anastomosing plexus of interconnecting vessels"
notype, which would make them less sensitive to VPF- were found in other tumors. The vasculature in tumors
inducing mechanisms. from the control melanoma lines resembled the first
Hypoxia is thought to be one of the major causes type, whereas in tumors from the VPF-transfected line
of tumor necrosis. In situ hybridization studies have the vasculature appeared to be more like the second
shown that VPF mRNA levels were highest around type. An altered VPF expression obviously is sufficient
necrotic sites in glioblastoma lesions, suggesting an for a switch from one vascular type to the other.
Involvement of hypoxia in the regulation of VPF ex- Studies from others, in which Chinese hamster
pression.14,15 However, in other tumor types most tu- ovary cells or HeLa cells were transfected with VPF,
mor cells produced VPF mRNA in abundance with 
only slightly increased levels being found adjacent to 
necrotic areas.46 In our study we found two sets of
showed that overexpression of VPF can lead to a 
growth advantage in nude mice, combined with 
higher angiogenic activity.51,52 The tumors from the
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VPF-transfected melanoma line used in our study did 
not show such behavior; they did not have a faster 
growth rate, and angiogenesis was qualitatively 
rather than quantitatively different. Obviously, angio­
genesis is too complex a process to have its outcome 
predicted by the level of VPF expression only. Simi­
larly, the vasculature in xenografts from transfectant 
line 1-3 might have been expected to be very much 
like that in xenografts from other constitutively VPF- 
producing melanoma lines such as BLM and MV3, 
but this was not at all the case (J. R. Westphal, 
J.A.W.M. van der Laak, C.J.M. Schalkwijk, D.J. Ruiter, 
R.M.W. de Waal, manuscript in preparation). VPF ex­
pression in line 1-3 was probably much higher than in 
lines BLM and MV3, and transfectant lines with a 
lower recombinant VPF exoression than line 1-3
■
should therefore be studied. Even then, VPF is prob­
ably not the only factor relevant to angiogenesis in 
these tumors; a number of other factors directly or 
indirectly involved in angiogenesis may be differen­
tially expressed between BLM and MV3 on one hand 
and Mel57 and its tranfectants on the other hand. Dif­
ferences in expression of various integrins and of pro­
teins involved in the plasminogen activator pathway 
have indeed been shown between some of these 
melanoma lines.25,5?4 The vascular phenotype in any 
tumor will be the result of a large number of factors 
influencing angiogenesis, but our study shows that 
VPF is at least one of the important factors governing 
angiogenesis in these melanoma xenografts.
Further study has to be undertaken to completely 
understand the way the aberrant vascular phenotype 
in tumors from line 1-3 evolves. Furthermore, it is an 
interesting question whether the altered VPF expres-
sion pattern le to a different degree of vascular
trac
fil)
■tu’¿ t  I  V J  *
for, eg, fibrinogen or for
addressing this issue are
We also hope to answer the initial question whether
Dtastatic poten-
? in r V f *tial of melanoma
as the constitutive expression of VPF by the
- 3 to a vascular phenotype
included in future studies on the correlation between 
VPF levels, vascular pattern, and metastasis,
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